BioMarin Pharmaceutical names new director
10 July 2019 -

BioMarin Pharmaceutical Inc (Nasdaq:BMRN), a company involved in providing therapies for rare genetic diseases, announced yesterday that it has named Liz McKee Anderson as its director effective 15 July 2019.

McKee Anderson serves on a number of boards, including biotechnology companies REVOLUTION Medicines Inc, Bavarian Nordic A/S, Insmed Inc, ARO Biotherapeutics Company, and Context Therapeutics. In addition, she serves on the board of Huntsworth PLC, an international healthcare and communications group. She also serves on the Board of Trustees for The Wistar Institute. Earlier, she served in marketing and operations roles with increasing levels of responsibility at Johnson & Johnson culminating in her role as the worldwide vice president, Infectious Diseases and Vaccines at Janssen where she directed the commercial development of an extensive portfolio of antivirals and vaccines, with responsibility for global marketing, access and analytics. While at Johnson & Johnson, she held a number of senior leadership roles in Immunology and Oncology and served on the Pharmaceuticals Group R&D Development Management Committee and operating company management boards. Prior to Johnson & Johnson, she served as the vice president and general manager of Wyeth Lederle Vaccines from 1997 to 2002. She also previously held executive commercial operating roles at Rhone Poulenc Rorer and the American National Red Cross.

Jean-Jacques Bienaime, chairman and chief executive officer at BioMarin, said, 'We are thrilled to have Liz join BioMarin's board of directors. She brings additional expertise in commercial operations and marketing in the biopharmaceutical industry to an already outstanding board. Liz's commercial experience in launching first-in-class and best-in-class therapies, as well as in developing product portfolio strategy is well suited to support BioMarin's growth, as we prepare for two potential product launches of therapies to treat patients with rare genetic diseases.'